Rhumbline Advisers Lowers Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Rhumbline Advisers reduced its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,058 shares of the medical instruments supplier’s stock after selling 337 shares during the period. Rhumbline Advisers owned 0.24% of Mesa Laboratories worth $1,722,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of MLAB. FMR LLC raised its stake in Mesa Laboratories by 34.1% during the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 100 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Mesa Laboratories during the 3rd quarter worth $70,000. Amalgamated Bank raised its position in shares of Mesa Laboratories by 6.5% in the 3rd quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier’s stock worth $206,000 after buying an additional 97 shares during the period. Captrust Financial Advisors purchased a new position in shares of Mesa Laboratories in the 3rd quarter worth $207,000. Finally, Berry Wealth Group LP boosted its holdings in Mesa Laboratories by 5.3% in the fourth quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier’s stock valued at $219,000 after acquiring an additional 83 shares during the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th.

Mesa Laboratories Price Performance

MLAB opened at $136.24 on Wednesday. Mesa Laboratories, Inc. has a 52-week low of $83.68 and a 52-week high of $155.12. The company has a 50 day moving average of $139.89 and a two-hundred day moving average of $129.51. The company has a market cap of $740.33 million, a P/E ratio of -2.95 and a beta of 0.83. The company has a quick ratio of 0.53, a current ratio of 0.71 and a debt-to-equity ratio of 0.61.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. On average, analysts expect that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, February 28th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.47%. Mesa Laboratories’s dividend payout ratio (DPR) is currently -1.38%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.